UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential
Researchers target thyroid cancer with triple threat drug combination
Combining a gene-targeted drug, a cancer-bursting virus and a drug
Scientists explore combination therapies for breast cancer brain metastases
Breast cancer is the most frequent neoplasm among women, impacting
Tethering together type 2 diabetes drugs increases efficacy of combination therapy
Biomedical engineers at Duke University have shown that the efficacy
Combination of chemo and diabetes drugs shows potential for treating Ewing sarcoma
Ewing sarcoma, an aggressive tumor that commonly affects bones in
One in two patients with metastatic melanoma alive after five years with combination immunotherapy
One in two patients with metastatic melanoma is alive with
New nanoparticle combination therapy shows effective resuscitation for massive hemorrhage
Massive hemorrhage, or excessive bleeding, is a potentially preventable yet
CD40 combination therapy can shrink pancreatic tumors
A new combination of immunotherapy and chemotherapy for pancreatic cancer
Drug combination may become new standard treatment for advanced kidney cancer
A combination of two drugs—one of them an immunotherapy agent—could
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc.